Why Should We Talk about Tardive Dyskinesia? An Introduction to Diagnosis and Treatment for Early-Career Clinicians

Why Should We Talk about Tardive Dyskinesia? An Introduction to Diagnosis and Treatment for Early-Career Clinicians

On-Demand Webcast
Program Details

Presented live at the Elevate 2018.


Rakesh Jain, MD, MPH
Clinical Professor,
Department of Psychiatry
Texas Tech Health Sciences
Center, School of Medicine
Midland, Texas

Joohi Jimenez-Shahed, MD
Assistant Professor of Neurology
Baylor College of Medicine
Houston, Texas

For full faculty bios, please call 609-371-1137.


Learning Objectives

After completing this activity, learners should be able to:

  • Describe the underlying biologic mechanisms that link the prevalence and risk of developing TD to the use of antipsychotic medication
  • Apply standardized tools for the optimal and continued assessment of at-risk patients to facilitate an accurate and timely TD diagnosis
  • Evaluate current approaches to TD management, both traditional methods and newer pharmacotherapies, with respect to their clinical efficacy, safety, and indications
  • Integrate the latest clinical evidence and current therapeutic options into individualized strategies for the prevention and treatment of TD
Activity Overview

In order to be eligible for documentation of credit, participants must attend the full webinar and complete the evaluation form. After successful completion of the evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

For questions regarding this educational activity, please call 609-371-1137.

No additional fee is required to attend this activity.


In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 0.75 contact hour.

Nurse Planner: Andrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, CA; Assistant Clinical Professor, University of California, San Francisco, CA

Independent Clinical Reviewer: William C. Torrey, MD, Professor of Psychiatry, Dartmouth’s Geisel School of Medicine, Hanover, New Hampshire; Associate Psychiatry Service Line Leader, Dartmouth-Hitchcock, Lebanon, New Hampshire

Planning Committee

The planning committee comprises Rakesh Jain, MD, MPH; Rajeev Kumar, MD; Joohi Jimenez-Shahed, MD; Andrew Penn, RN, MS, NP, CNS, APRN-BC; and Meaghan Benci, Raquel Gaerlan, Amy Ghiretti, PhD, Jennifer Ilcyn, Randy Robbin, Horacio Rodriguez, Kelly Sweeney, and Susan Yarborough.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty reported the following:

Dr. Rakesh Jain: Advisory Board—Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, and Teva; Consultant—Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Consultant (spouse)—Lilly, Otsuka, Pamlab, Sunovion; Grant/Research Support—AstraZeneca, Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers’ Bureau—Addrenez, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, and Tris Pharmaceuticals

Dr. Rajeev Kumar: Consultant—Teva, Acadia, Adamas, Axovant; Speaker’s Bureau—Teva, Acadia, Allergan, Abbvie, Adamas, Neurocrine, US World Meds; Research Support—Accorda. Teva, Auspex, US World Meds. Kyowa. Neuroderm, Civitas, Jazz, Enterin,  NINDS, Prexton, Axovant, AbbVie, Biogen, Roche, CHDI, Dart,l

Dr. Joohi Jimenez-Shahed: Consultant—Teva Pharmaceuticals; Educational Grants—Neurocrine Biosciences and Teva Pharmaceuticals

Mr. Penn and Dr. Torrey have disclosed no relevant financial relationships with any commercial interests.

Ms. Benci Ms. Gaerlan, Ms. Ghiretti, Ms. Ilcyn, Mr. Robbin, Mr. Rodriguez, Ms. Sweeney and Ms. Yarborough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that no off-label/unapproved use(s) of drugs and/or devices will be discussed.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC (NACCME). All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

ADA Statement

North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

Grant Support

This activity has been supported through independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.